Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis - 11/10/20

Doi : 10.1016/j.ajem.2020.05.073

Brandon Michael Henry, MD ^a,^{^⁎} , Gaurav Aggarwal, MD ^b, Johnny Wong ^c, Stefanie Benoit, MD ^d,^e, Jens Vikse ^f, Mario Plebani ^g, Giuseppe Lippi, MD ^h
^a Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
^b Department of Medicine, Jersey City Medical Center, Jersey City, NJ, USA
^c College of Medicine, SUNY Downstate Health Sciences University, New York, USA
^d Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, OH, USA
^e Department of Pediatrics, College of Medicine, University of Cincinnati, OH, USA
^f Department of Clinical immunology, Stavanger University Hospital, Stavanger, Norway
^g Department of Lab Medicine, University Hospital, Padova, Italy
^h Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy

^⁎Corresponding author at: Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.Cardiac Intensive Care UnitThe Heart InstituteCincinnati Children's Hospital Medical Center3333 Burnet AvenueCincinnatiOH45229USA

connettersi o creare un account

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Coronavirus disease 2019 (COVID-19) infection has now reached a pandemic state, affecting more than a million patients worldwide. Predictors of disease outcomes in these patients need to be urgently assessed to decrease morbidity and societal burden. Lactate dehydrogenase (LDH) has been associated with worse outcomes in patients with viral infections. In this pooled analysis of 9 published studies (n = 1532 COVID-19 patients), we evaluated the association between elevated LDH levels measured at earliest time point in hospitalization and disease outcomes in patients with COVID-19. Elevated LDH levels were associated with a ~6-fold increase in odds of developing severe disease and a ~16-fold increase in odds of mortality in patients with COVID-19. Larger studies are needed to confirm these findings.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Lactate dehydrogenase, COVID-19, Coronavirus

Mappa

Introduction

Methods

Search design

Selection and data collection

Statistical analysis

Results

Study identification and characteristics of studies

Pooled analysis of disease severity

Pooled analysis of mortality

Discussion

Conclusion

CRediT authorship contribution statement

Esportazione

Vol 38 - N° 9

P. 1722-1726 - settembre 2020 Ritorno al numero

Articolo precedente

Critical procedure performance in pediatric patients: Results from a national emergency medicine group
Jestin N. Carlson, Mark S. Zocchi, Coburn Allen, T. Kent Denmark, Jay D. Fisher, Matthew Wilkinson, Katherine Remick, Abbie Sullivan, Jesse M. Pines, Arvind Venkat, US Acute Care Solutions Research Group

| Articolo seguente

COVID-19 in health care workers – A systematic review and meta-analysis
Ankit Kumar Sahu, V.T. Amrithanand, Roshan Mathew, Praveen Aggarwal, Jamshed Nayer, Sanjeev Bhoi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

connettersi o creare un account

Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis - 11/10/20

Abstract

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL